P&G closes buy of Merck KGaA’s consumer health business

Press enter to search
Close search
Open Menu

P&G closes buy of Merck KGaA’s consumer health business

12/03/2018
Procter & Gamble now has a larger consumer brand portfolio and geographic scale. The company announced Friday that it had completed its €3.2 billion acquisition of Darmstadt, Germany-based Merck KGaA’s consumer health business.

The company said the acquisition increases its footprint in most of the world’s top 15 OTC markets. Top brands that join the Cincinnati-based company’s portfolio include Neurobion, Dolo-Neurobion, Femibion, Nasivin, Bion3, Seven Seas and Kytta — all of which are sold largely in Europe, Latin America and Asia.

As part of the acquisition, Merck KGaA’s Uta Kemmerich-Keil — formerly president and CEO — joins P&G as the leader of P&G Personal Healthcare International, an organization that encompasses the newly combined OTC business in Europe, Latin America and Asia, as well as India, the Middle East and Africa.

“Today marks the beginning of an exciting new era for P&G Personal Health Care, as we now move forward to realize the great potential of our combined businesses,” said Tom Finn, president of P&G Global Personal Health Care. “In bringing Merck KGaA, Darmstadt, Germany, Consumer Health into P&G, we have created a new healthcare organization that is well-positioned to enable consumers to live longer, healthier and more vibrant lives, as well as drive further sales and profit growth for P&G.”